Latest Headlines

1. Queen’s And Almac Discovery Launch State-Of-The-Art Chemoproteomics Facility In Belfast 11/29/2023

   The multi-million-pound facility, which is jointly funded by Almac Discovery and a BBSRC Prosperity Partnership award, is a first of its kind in Northern Ireland and will be located at Queen’s.

2. Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant For Clinical Trial On Experimental AML/MDS Treatment 11/28/2023

   Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates.

3. Carisma Therapeutics Announces FDA Clearance Of IND Application For CT-0525, A Novel HER2-Targeting CAR-Monocyte 11/28/2023

   Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).

4. Scientists Harness Flower ‘Super Power’ To Pave The Way For New Drug Treatments 11/28/2023

   Scientists at the University of Bath have used nature as inspiration in developing a new tool that will help researchers develop new pharmaceutical treatments in a cleaner, greener, and less expensive way.

5. Orexo Announces FDA Acceptance Of New Drug Application Filing For OX124, A High-Dose Rescue Medication For Opioid Overdose 11/28/2023

   Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the New Drug Application (NDA) for OX124 has been accepted for review by the US Food and Drug Administration (FDA).

6. Evommune And Accutar Biotechnology Announce AI Drug Discovery Collaboration 11/28/2023

   Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, and Accutar Biotechnology Inc., a company focusing on artificial intelligence (AI)-empowered drug discovery, today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.

7. PRISM BioLab And Lilly Enter Into A Drug Discovery Collaboration On A Protein-Protein Interaction Target 11/28/2023

   PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company ("Lilly").

8. Renewed Partnership To Boost The Skills Needed To Drive Drug Discovery And Development In Africa 11/27/2023

   The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and H3D Foundation have today announced a new three-year phase of their partnership, aiming to boost the skills and capacity needed to drive increased research and development of new medicines in Africa.

9. Arcturus Therapeutics Receives Orphan Drug Designation From The U.S. FDA For ARCT-032, For The Treatment Of Cystic Fibrosis 11/27/2023

   Arcturus Therapeutics Holdings Inc a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s product candidate ARCT-032 to treat cystic fibrosis (CF).

10. Artificial Intelligence Finds Ways To Develop New Drugs 11/23/2023

    New active pharmaceutical ingredients lay the foundations for innovative and better medical treatments. However, identifying them and, above all, producing them through chemical synthesis in the laboratory is no mean feat.